Eli Lilly (NYSE:LLY) has acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix proteolipid vehicle (PLV) drug-delivery technology.
Indianapolis-based Lilly plans on using the platform to discover and develop nucleic acid products intended for the nervous system.
Lilly is optimistic that Fusogenix could help it address hurdles tied to nucleic acid therapeutic modalities.
In the collaboration, Edmonton, Canada–based Entos will focus on creating and optimizing PLVs, while Lilly will select PLVs it intends to use for clinical development and commercialization.
The Fusogenix platform delivers a proteo-lipid vehicle (PLV) payloadinto the cytoplasm. Fusogenix image courtesy of Entos Pharmaceuticals
Lilly will pay Entos $50 million upfront and could pay up to $400 million in additional milestone payments. Entos also could receive royalties from commercialized products stemming from…